90 likes | 665 Views
NanoCrystal Technology Elan Corp., Dublin, Ireland. Improves the delivery of drugs with low water solubility by using a proprietary
E N D
1. Nanotechnology Advances in Drug Delivery
Susan DesJardin
Based on June 2007 Article in Pharmaceutical Technology Magazine
2. NanoCrystal Technology Elan Corp., Dublin, Ireland Improves the delivery of drugs with low water solubility by using a proprietary “wet-milling” process to form nanometer size particles followed by surface absorption of select stabilizers to prevent agglomeration.
3. FDA-Approved NanoCrystal Technology Products Wyeth’s Rapamune (sirolimus) – immuno-suppressive agent
Merck’s Emend (aprepitant) – antiemetic (prevents nausea in cancer therapy)
Abbott Lab’s Tricor (fenofibrate) – reduce LDL cholesterol and total triglycerides
Par Pharmaceutical’s Megace ES (megestrol) – anorexia and weight loss in AIDS patients
4. Nanoedge Technology Baxter Healthcare “The particle size is reduced to nanometer size to increase the surface area, thereby, increasing the rate of dissolution by using two complementary processes, homogenization and precipitation.”
5. BioSilicon TechnologypSivida (Australia) Elemental silicon processed to create a honeycomb structure of pores of various shapes and sizes that can be filled with drugs.
This technology is targeted for drugs with low water solubility and controlled, slow release drugs.
BrachySil (Phase II trials) delivers radioactive agents directly to tumors via inhalation.
6. Cyclosert TechnologyInsert Therapeutics Nano-engineered linear cyclodextrin- containing polymer
Targeted for the delivery of small molecules and nucleic acids
Licensed to R&D Biopharmaceuticals GmbH (Germany) for anti-cancer agent tubulysin A
7. Nanotechnology Development in Academia Princeton Univ. – “Flash Nano-Precipitation” process for mixing drugs and binder materials to create nanosize particles – targeted for inhalation drugs
Univ of Penn. – 20 nm dia. cylinders deliver the anticancer drug paclitaxel to tumors in mice, cylinders stay in the circulatory system for up to one week
8. Regulatory Perspective National Nanotechnology Initiative (NNI) coordinates the multi-agency efforts in nanoscience including FDA and 22 other federal agencies
FDA has formed a NanoTechnology Interest Group made up representatives of all its agencies
FDA launched the Nanotechnology Task Force in 2006 to facilitate the safe and effective use of nanoengineered materials in FDA-regulated products.
9. National Cancer Institute Alliance for Nanotechnology in Cancer was formed in 2005 including both the public and private sector to accelerate the application of nanotechnology to cancer treatment.
Under the nano-subcommittee of the Interagency Oncology Task Force; FDA, NCI and NIST are working together to advance nanotechnology for oncology.